Lv4
460 积分 2024-01-20 加入
Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
11小时前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
1个月前
已完结
Adjuvant sintilimab effective in high-risk HCC
1个月前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
1个月前
已完结
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
3个月前
已完结
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
5个月前
已完结
Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study
6个月前
已完结
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
6个月前
已完结
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
7个月前
已关闭
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
7个月前
已关闭
皖公网安备34019202002308
